生物学杂志 ›› 2023, Vol. 40 ›› Issue (2): 1-.doi: 10.3969/j.issn.2095-1736.2023.02.001

• 特约综述 •    下一篇

盘状结构域受体1(DDR1):实体肿瘤治疗的新靶点

舒 航1, 金腾川2,3, 王 华1,4   

  1. 1. 安徽医科大学第一附属医院肿瘤科, 合肥 230022; 2. 中国科学技术大学生命科学与医学部,
    合肥 230000; 3. 合肥综合性国家科学中心大健康研究院, 合肥 230000;
    4. 安徽医科大学炎症免疫性疾病安徽省实验室, 合肥 230000
  • 出版日期:2023-04-18 发布日期:2023-04-18
  • 通讯作者: 金腾川,教授,博士生导师,研究方向为感染与免疫的结构生物学,E-mail: jint@ustc.edu.cn;王华,教授,博士生导师,研究方向为肝脏的损伤与修复、肿瘤免疫微环境,E-mail: wanghua@ahmu.edu.cn;金腾川和王华为共同通信作者)
  • 作者简介:舒航,博士研究生,研究方向为肿瘤的免疫治疗,E-mail: shuhang0808@126.com
  • 基金资助:
    国家自然科学基金联合项目(U21A20375)

Discoidin domain receptor 1 (DDR1): a new drug target for solid tumors

SHU hang1, JIN Tengchuan2,3, WANG Hua1,4   

  1. 1. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China;
    2. Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230000, China;
    3. Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230000, China;
    4. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230000, China
  • Online:2023-04-18 Published:2023-04-18

摘要: 盘状结构域受体家族(discoidin domain receptors, DDRs)成员DDR1广泛表达于人体正常组织,与肿瘤的发生发展密切相关,基于DDR1本身的结构和生物学特点,围绕DDR1在肿瘤研究的进展展开综述,阐述DDR1对肿瘤细胞的增殖生存、迁移侵袭、上皮间质转化和细胞代谢的影响,以及DDR1对肿瘤微环境的重要作用,同时分析以DDR1为靶点的抗肿瘤药物的研究进展,以期为DDR1作为实体肿瘤治疗的新靶点提供理论依据和临床参考。

关键词: 盘状结构域受体1, 肿瘤, 信号通路, 肿瘤微环境

Abstract: DDR1, a member of the discoidin domain receptor family (DDRs), is widely expressed in human normal tissues and is closely related to the genesis and development of tumors. Based on the structure and biological characteristics of DDR1, this paper reviews the research progress of DDR1 in tumor, expounds the effects of DDR1 on tumor cell proliferation, survival, migration, invasion, epithelial interstitial transformation, and cell metabolism, as well as the important role of DDR1 in tumor microenvironment, and summarizes the progress of anti-tumor drugs targeting DDR1. The study aims to provide theoretical basis and clinical reference for DDR1 as a new target for solid tumor therapy in the future.

Key words: discoidin domain receptor 1, tumor, signaling pathway, tumor microenvironment

中图分类号: